Bioxytran Marks 50 years of Mitochondrial Research with BXT-25 Advancements
Rhea-AI Summary
Bioxytran (OTCQB: BIXT) commemorates 50 years of mitochondrial research advancement, highlighting the historical significance of fiber optic-based fluorometry in brain mitochondrial research through a landmark paper by Prof. Avraham Mayevsky of Bar-Ilan University.
The company's lead drug candidate BXT-25 is advancing toward Phase 1 trials, targeting conditions requiring oxygen transport carrier capabilities, including:
- Ischemic stroke
- Heart attack
- Pulmonary embolism
- Chronic kidney disease (CKD)
- Long Covid
The research emphasizes real-time mitochondrial monitoring through the MDX Viewer, an FDA-approved device measuring tissue metabolic score. The company is exploring partnerships to integrate next-generation monitoring technologies for patient selection and vital sign measurements.
Positive
- BXT-25 advancing to Phase 1 trials for multiple major medical conditions
- Integration with FDA-approved MDX Viewer device for real-time monitoring
- Potential partnerships for next-generation monitoring technologies
Negative
- Still in pre-clinical phase with no human trial data yet
- Multiple competing indications may complicate development pathway
News Market Reaction
On the day this news was published, BIXT gained 0.05%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
- The universal oxygen carrier delivery capabilities of BXT-25 can be monitored, broadening its applications to treat hypoxic diseases
- Leading drug candidate ProLectin-M targets galectins in viral infections including bird flu like viruses
BOSTON, MASSACHUSETTS, April 11, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing novel therapies targeting hypoxia and mitochondrial dysfunction, today highlighted the historical and scientific significance of fiber optic–based fluorometry in brain mitochondrial research. A landmark paper by Prof. Avraham Mayevsky of Bar-Ilan University was published in a book compiled by editor George Laliotis which covered key areas of biological science. Bioxytran believes this is a milestone achievement because the study, commemorates 50 years of in vivo NADH redox state monitoring, highlighting the pivotal role of mitochondrial function in cellular health. This is a cornerstone of Bioxytran’s BXT-25 drug development program.
https://doi.org/10.1117/1.JBO.30.S2.S23902
The recent paper emphasizes the significance of real-time mitochondrial monitoring, particularly in addressing mitochondrial dysfunction and hypoxia—key contributors to diseases like stroke.
The groundbreaking work of Prof. Mayevsky, which introduced UV-transmitting optical fibers for tracking NADH fluorescence in vivo, paved the way for development of the MDX Viewer with is an FDA approved device that measures tissue metabolic score in real time.
Bioxytran is advancing BXT-25 toward Phase 1 trials for conditions where an oxygen transport carrier is needed to burrow through blood clots including ischemic stroke, heart attack, pulmonary embolism, chronic kidney disease (CKD), and Long Covid. The company is also exploring partnerships to integrate next-generation monitoring technologies for patient selection and use as a new vital sign.
“This anniversary paper mirrors our mission at Bioxytran —to translate decades of foundational science into life-saving therapies,” stated David Platt, CEO of Bioxytran Inc. “BXT-25 builds on these principles by directly addressing the mitochondrial dysfunction observed in hypoxia-related diseases. Prof. Mayevsky’s work validates the urgency of our clinical efforts."
About Bioxytran, Inc.
Bioxytran, Inc. is at the forefront of developing complex carbohydrate-based therapeutics to address critical unmet medical needs in its three core platform technologies. These include virology, cancer metastasis, and oxygen transport. In addition to ProLectin-M, Bioxytran is advancing programs for pulmonary fibrosis and stroke treatment. For more information, visit www.bioxytraninc.com
Investor Relations
Michael Sheikh
509-991-0245
mike.sheikh@bioxytraninc.com
Forward-Looking Statements
This press release includes forward-looking statements as defined under federal law, including those related to the performance of technology described in this press release. These forward-looking statements are generally identified by the words “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” and similar expressions, although not all forward-looking statements contain these identifying words. Such statements are subject to significant risks, assumptions and uncertainties. Known material factors that could cause Bioxytran’s actual results to differ materially from the results contemplated by such forward-looking statements are described in the forward-looking statements and risk factors in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and those risk factors set forth from time-to-time in other filings with the Securities and Exchange Commission. Bioxytran undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events, or otherwise, except to the extent required under federal securities laws.
FAQ
What medical conditions is Bioxytran's BXT-25 targeting in Phase 1 trials?
How does BIXT's BXT-25 technology relate to mitochondrial research?
What monitoring technology is being used with BIXT's BXT-25 development?
What is the significance of Prof. Mayevsky's research for BIXT's drug development?
